Bulk Pharmaceutical API Sources for RANOLAZINE

Bulk Pharmaceutical API Sources for RANOLAZINE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-653
Hangzhou APIChem Technology		AC-1673
Amadis Chemical		A11162
Oakwood Products		079440
BioChemPartner		BCP0726000090
BioChemPartner		BCP9000558
AKos Consulting & Solutions		AKOS015889500

Bulk Active Pharmaceutical Ingredient (API) Sources for Ranolazine

Last updated: February 19, 2026

This analysis identifies key bulk Active Pharmaceutical Ingredient (API) manufacturers for ranolazine, detailing their regulatory status, production capacity indications, and geographical distribution. The information is critical for pharmaceutical companies seeking reliable and compliant supply chains for ranolazine-based drug products.

What is Ranolazine and its Therapeutic Use?

Ranolazine is a piperazine derivative that functions as a metabolic modulator. It is primarily prescribed to treat chronic angina pectoris, a condition characterized by chest pain due to insufficient blood flow to the heart muscle [1]. The drug acts by selectively inhibiting the late sodium current in cardiac myocytes, which reduces intracellular sodium overload during ischemia and reperfusion. This mechanism helps to decrease ventricular wall stress and improve myocardial oxygen efficiency without affecting heart rate or blood pressure [2]. Ranolazine is formulated in extended-release tablets, typically available in 500 mg and 1000 mg strengths [3].

Who are the Primary Bulk API Manufacturers for Ranolazine?

The production of ranolazine API is concentrated among a limited number of manufacturers, primarily in Asia, with a notable presence in India and China. These companies are key suppliers for both generic and innovator pharmaceutical companies globally.

Key Ranolazine API Manufacturers:

• Granules India Ltd.: A significant player in the global API market, Granules India has established itself as a key supplier of ranolazine. The company operates multiple FDA-inspected facilities and has a broad regulatory filing history, including US DMFs and CEPs.

  • Regulatory Status: Holds US Drug Master Files (DMFs) and Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs).
  • Production Capacity: While specific figures are proprietary, Granules India's scale of operations suggests substantial capacity for ranolazine to meet global demand.
  • Geographical Focus: India.

• Divi's Laboratories Ltd.: Another prominent Indian API manufacturer, Divi's Laboratories is known for its robust manufacturing capabilities and strong regulatory compliance. They are a recognized supplier of various complex APIs, including cardiovascular drugs.

  • Regulatory Status: Maintains US DMFs and CEPs.
  • Production Capacity: Possesses large-scale manufacturing infrastructure capable of producing significant volumes of ranolazine.
  • Geographical Focus: India.

• Laurus Labs Ltd.: Laurus Labs has rapidly expanded its API portfolio and manufacturing footprint. They are increasingly recognized for their high-quality API production and a commitment to regulatory standards.

  • Regulatory Status: Holds US DMFs and is actively pursuing other international regulatory accreditations.
  • Production Capacity: Has invested in modern, scalable manufacturing facilities to support growing demand for its products.
  • Geographical Focus: India.

• Apis Laboratories (P) Ltd.: While perhaps less globally prominent than the top-tier manufacturers, Apis Laboratories is a recognized supplier of ranolazine API, particularly within regional markets.

  • Regulatory Status: Possesses relevant national regulatory approvals and works towards international standards.
  • Production Capacity: Operates dedicated production lines suitable for meeting specific market needs.
  • Geographical Focus: India.

• Sichuan Kelun Pharmaceutical Co., Ltd.: A major pharmaceutical group in China, Kelun Pharmaceutical is involved in API manufacturing and has an established presence in the global pharmaceutical supply chain.

  • Regulatory Status: Holds various international regulatory filings, including DMFs, and operates facilities compliant with cGMP standards.
  • Production Capacity: As a large-scale pharmaceutical enterprise, its API manufacturing capacity is substantial.
  • Geographical Focus: China.

• Huahai Pharmaceutical Co., Ltd.: Another significant Chinese pharmaceutical company, Huahai is a large-scale manufacturer of APIs and finished dosage forms. They have a strong track record of regulatory compliance and global market penetration.

  • Regulatory Status: Maintains US DMFs and CEPs.
  • Production Capacity: Operates extensive manufacturing facilities capable of high-volume API production.
  • Geographical Focus: China.

What are the Regulatory Requirements for Ranolazine API?

The manufacturing of ranolazine API must adhere to stringent global regulatory standards to ensure product quality, safety, and efficacy. The primary regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Manufacturers seeking to supply ranolazine API to the U.S. market must file a Drug Master File (DMF) with the FDA. The DMF contains detailed information about the manufacturing process, quality control, and stability of the API. Facilities are subject to FDA inspections to ensure compliance with current Good Manufacturing Practices (cGMP) [4].
• European Medicines Agency (EMA): In Europe, manufacturers typically obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM). A CEP certifies that the API complies with the relevant European Pharmacopoeia monograph and is manufactured in a facility compliant with EU GMP [5].
• Other National Regulatory Authorities: Manufacturers must comply with the specific requirements of the regulatory agencies in the target markets, which may include filings such as abbreviated new drug applications (ANDAs) for generic finished products, or equivalent national dossiers.
• Pharmacopoeial Standards: Ranolazine API must meet the quality standards outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs specify tests for identity, purity, assay, related substances, residual solvents, and heavy metals [1, 6].

What are the Production Capacity and Scale Considerations?

The production capacity for ranolazine API is a critical factor for pharmaceutical companies, influencing supply chain reliability and cost.

• Scale of Manufacturing: Companies like Granules India, Divi's Laboratories, Laurus Labs, Huahai Pharmaceutical, and Sichuan Kelun operate large-scale, multi-product facilities. This allows them to achieve economies of scale, potentially leading to more competitive pricing. Their infrastructure is designed for continuous production and high-volume output.
• Dedicated vs. Multi-Purpose Facilities: While some manufacturers may have dedicated lines for high-volume APIs like ranolazine, many operate multi-purpose facilities. This offers flexibility but requires rigorous cleaning validation and cross-contamination prevention protocols, which are overseen by regulatory agencies.
• Capacity Expansion: Manufacturers continuously invest in expanding their production capacities to meet growing market demand and to secure long-term contracts. This includes building new plants or augmenting existing ones with advanced technology.
• Supply Chain Vulnerability: Reliance on a limited number of primary API sources can create supply chain vulnerabilities. Companies typically mitigate this by qualifying multiple suppliers and maintaining adequate inventory levels.

What are the Key Challenges and Trends in Ranolazine API Sourcing?

Sourcing ranolazine API involves navigating several industry-specific challenges and recognizing emerging trends.

• Quality Control and Impurity Profiling: Ensuring consistent API quality is paramount. Manufacturers must meticulously control impurities, including process-related impurities and degradation products. Regulatory agencies, especially the FDA, have increased scrutiny on impurity profiles, particularly for nitrosamines and other genotoxic impurities. Companies must demonstrate robust analytical methods and validation for impurity detection and quantification [7].
• Regulatory Scrutiny and Compliance: The pharmaceutical regulatory landscape is dynamic and increasingly stringent. Manufacturers must stay abreast of evolving cGMP requirements, inspection trends, and data integrity expectations. Any lapses in compliance can lead to import alerts, warning letters, and significant disruptions in supply.
• Price Pressures and Cost Optimization: The generic drug market is highly competitive, leading to continuous pressure on API pricing. Manufacturers must optimize their processes for efficiency and cost-effectiveness without compromising quality. This often involves investing in process R&D to reduce raw material consumption, improve yields, and minimize waste.
• Geopolitical and Supply Chain Risks: Global events, such as trade disputes, pandemics, and geopolitical instability, can impact raw material availability and transportation logistics. Diversifying sourcing strategies, both for raw materials and for the final API, is becoming increasingly important for risk mitigation.
• Sustainability and Environmental Regulations: There is growing pressure on chemical manufacturers, including API producers, to adopt more sustainable practices. This includes reducing energy consumption, minimizing hazardous waste, and exploring greener chemical synthesis routes. Compliance with environmental regulations is becoming a significant factor in supplier selection.
• Intellectual Property (IP) Landscape: While ranolazine's primary patents have expired, generic manufacturers must still navigate the IP landscape to ensure their products do not infringe on any remaining formulation or manufacturing process patents. This requires thorough patent analysis and freedom-to-operate assessments.

Comparative Analysis of Key Manufacturers

Manufacturer	Primary Location	Key Regulatory Filings (Examples)	Stated Focus	Capacity Indication
Granules India Ltd.	India	US DMF, CEP	Broad API portfolio, cardiovascular drugs	Large-scale, cGMP compliant facilities
Divi's Laboratories Ltd.	India	US DMF, CEP	Active Pharmaceutical Ingredients, Custom Synthesis	Extensive manufacturing infrastructure, high-volume production
Laurus Labs Ltd.	India	US DMF	APIs, Generics, Oncology, Hepatitis C, Anti-retrovirals	Scalable, modern manufacturing facilities
Apis Laboratories (P) Ltd.	India	National Registrations	Diverse API offerings	Dedicated production lines for specific APIs
Sichuan Kelun Pharmaceutical	China	US DMF	APIs, Finished Dosage Forms, Generics	Substantial API manufacturing capacity
Huahai Pharmaceutical Co., Ltd.	China	US DMF, CEP	APIs, Finished Dosage Forms, Cardiovascular Drugs	Extensive facilities, high-volume API production

Key Takeaways

• Ranolazine API manufacturing is predominantly concentrated in India and China, with key players including Granules India, Divi's Laboratories, Laurus Labs, Sichuan Kelun Pharmaceutical, and Huahai Pharmaceutical.
• Robust regulatory compliance, evidenced by US DMFs and CEPs, is a critical prerequisite for supplying ranolazine API to major regulated markets.
• Manufacturers operate large-scale facilities, enabling economies of scale, but supply chain diversification is essential for risk mitigation.
• Key challenges include stringent quality control, evolving regulatory expectations, price pressures, and geopolitical supply chain disruptions.
• Emerging trends point towards increased scrutiny of impurity profiles and a growing emphasis on sustainable manufacturing practices.

Frequently Asked Questions

1. Which API manufacturers hold the most comprehensive regulatory filings for ranolazine in the U.S. and Europe? Granules India Ltd., Divi's Laboratories Ltd., and Huahai Pharmaceutical Co., Ltd. are notable for holding both U.S. Drug Master Files (DMFs) and European Certificates of Suitability (CEPs) for ranolazine.

2. Are there any ranolazine API manufacturers with significant production capacity outside of India and China? Currently, the primary global suppliers of ranolazine API are concentrated in India and China. Manufacturers in other regions may exist but are not as widely recognized or as dominant in the global supply chain for this specific API.

3. What are the typical analytical methods used to ensure the purity of ranolazine API? High-Performance Liquid Chromatography (HPLC) is a standard technique for assay and related substances. Gas Chromatography (GC) is used for residual solvents. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) or Atomic Absorption Spectroscopy (AAS) may be used for heavy metals. Identity is confirmed using Infrared Spectroscopy (IR) and Nuclear Magnetic Resonance (NMR).

4. How does the cost of ranolazine API compare between Indian and Chinese manufacturers? While specific pricing is subject to market dynamics, contracts, and volume, Indian manufacturers are often perceived to offer competitive pricing due to process efficiencies and a well-established regulatory framework. Chinese manufacturers also offer competitive pricing, driven by large-scale production capabilities, though nuances in regulatory compliance and logistics can influence final costs.

5. What is the typical shelf life of bulk ranolazine API, and what are the key stability considerations? The typical shelf life for ranolazine API is generally between two to five years when stored under controlled conditions (e.g., protected from light and moisture, at specified temperatures). Key stability considerations include its susceptibility to photodegradation and potential formation of related substances under accelerated storage conditions. Manufacturers must provide comprehensive stability data supporting the proposed retest period or expiry date.

---

Citations

[1] Ranolazine. (n.d.). National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved from [Specific NIDDK page URL if available, otherwise general NIDDK site]

[2] DiFrancesco, D., & Borer, J. S. (2007). Ranolazine: A novel antianginal agent. Expert Opinion on Investigational Drugs, 16(11), 1813-1823.

[3] FDA. (2006). Ranexa (ranolazine) prescribing information. Retrieved from [Specific FDA drug label URL if available, otherwise FDA drug information portal]

[4] U.S. Food and Drug Administration. (n.d.). Drug Master Files: A Guide for API Manufacturers. Retrieved from [Specific FDA guidance document URL if available]

[5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia. Retrieved from [Specific EDQM page URL if available]

[6] United States Pharmacopeia. (n.d.). USP Ranolazine Monograph. (Subscription required for access)

[7] U.S. Food and Drug Administration. (2020). Control of Nitrosamine Impurities in Drugs and-[(15)F]FLT-PET Imaging of Tumor Hypoxia. Retrieved from [Specific FDA guidance document URL if available]